Bilateral Acute Iris Transillumination (BAIT) syndrome is a unique, uncommon,
drug-related ocular condition that presents with bilateral pigment dispersion,
diffuse iris transillumination, and raised intraocular pressure (IOP), usually
triggered by the fluoroquinolone compound moxifloxacin. The patients typically
developed severe symptoms, including photophobia, unfocused vision, mid-dilated
nonreactive pupils, and ocular pain. Because of its varied similarities among
diseases such as viral anterior uveitis and pigment dispersion syndrome, bilateral
anterior uveitis and iridocyclitis is often misdiagnosed; thus, patients are treated
wrongly with excessive corticosteroid administration. This review explores the
geographic distribution, clinical features, underlying risk factors, and potential
mechanisms involved in BAIT, with particular emphasis on its strong association
with oral moxifloxacin use. BAIT seems more common in 30 to 50-year-old females,
with most cases described in Turkey and southern Europe and likely underdiagnosed
in other parts of the world. Treatment is symptomatic or control of IOP
with topical hypotensive agents, and corticosteroids are contraindicated. BAIT is
typically self-limiting but has the potential to cause temporary or permanent vision
effects. BAIT is an essential entity to recognize for accurate diagnosis and
management, and further research is needed to better elucidate its long-term
consequences and pathophysiology.
Keywords: bilateral acute iris transillumination, BAIT syndrome, moxifloxacin,
pigment dispersion, differential diagnosis